Human Genome Sciences, Inc.announced today that its presentation at the BioCentury - Thomson Financial 13th Anniversary NewsMakers in the Biotech Industry conference will be webcast and may be accessed

The need for accurate testing of cholesterol and liver function in Accutane patients is underscored by a study released last week by the University of California, San Francisco, and published in the Archives of Dermatology.

Increasingly, U.S. community cancer centers are among the diverse clinical environments pioneering the use of Elekta Synergy(R) systems, the leading commercial system for treating cancer patients using Intensity Modulated Radiation Therapy (IMRT) and Image Guided Radiation Therapy (IGRT).

Millennium Pharmaceuticals, Inc.  today announced the initiation of a Phase I study of MLN0415, an oral, highly selective, small molecule inhibitor of IKK2, which targets a major inflammatory pathway. The randomized, double-blind, placebo-controlled study will enroll up to 72 healthy volunteers and assess safety, tolerability,